Basel, June 12, 2022 Novartis today announced long-term results from the ELIANA pivotal clinical trial of Kymriah (tisagenlecleucel), the first-ever approved CAR-T cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL), with a maximum survival follow-up of 5.9 years. For the 79 patients treated with Kymriah in this study, the five-year overall survival (OS) rate was 55% (95% CI, 43-66), while the median event-free survival (EFS) for patients in remission within three months of infusion (n=65) was 43.8 months. These findings demonstrate the curative potential of Kymriah, the only CAR-T cell therapy available for these patients who previously had limited treatment options. These data were presented as an oral presentation during the 2022 European Hematology Association (EHA) Hybrid Congress (Abstract #S112)1.

These data mark a moment of profound hope for children, young adults and their families with relapsed or refractory B-cell ALL, as relapse after five years is rare, said Stephan Grupp, MD, PhD, Section Chief of the Cellular Therapy and Transplant Section, and Inaugural Director of the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy at Children's Hospital of Philadelphia (CHOP). Since the approval of Kymriah nearly five years ago, we have been able to offer a truly game-changing option to patients who previously faced a five-year survival rate of less than 10 percent.

This long-term follow up of ELIANA demonstrated the potential for Kymriah to transform cancer treatment in pediatric and young adult patients with r/r B-cell ALL, significantly improving outcomes with durable responses and a consistent safety profile in this patient population1:

At Novartis, we strive for cures. With nearly six-year follow-up data in these pediatric and young adults treated for B-cell ALL, we have our strongest evidence yet that one-time treatment with Kymriah has curative potential, said Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development. These results strengthen our confidence in CAR-T cell therapies as a truly transformative and paradigm-shifting advance in cancer care, as well as our commitment to continue developing this technology with next-generation platforms.

Additional updates on the Novartis CAR-T program presented at the 2022 EHA Congress include new data from more patients and longer follow-up from the first-in-human dose-escalation trials with YTB323 in adults with r/r diffuse large B-cell lymphoma and PHE885 in adults with r/r multiple myeloma, the first Novartis CAR-T cell therapies developed using the Novartis T-Charge platform2,3,4. Visit https://www.hcp.novartis.com/virtual-congress/eha-2022/ to learn more about these data and our ongoing commitment to reimagining cancer care with CAR-T cell therapies.

About KymriahKymriah is the first-ever FDA-approved CAR-T cell therapy. It is a one-time treatment designed to empower patients immune systems to fight their cancer. Kymriah is currently approved for the treatment of r/r pediatric and young adult (up to and including 25 years of age) acute lymphoblastic leukemia (ALL), r/r adult diffuse large B-cell lymphoma (DLBCL) and r/r adult follicular lymphoma1.

About the ELIANA TrialELIANA was the first pediatric global CAR-T cell therapy registration trial, examining patients in 25 centers in 11 countries across the US, Canada, Australia, Japan and the EU, including: Austria, Belgium, France, Germany, Italy, Norway and Spain. The trial was an open-label, multicenter, single-arm, global Phase II trial investigating the efficacy and safety of Kymriah in pediatric and young adult patients in r/r B-cell ALL who were primary refractory, chemorefractory, relapsed after, or were not eligible for allogeneic stem cell transplantation (SCT). The primary endpoint was overall remission rate (ORR), defined as best overall response of CR or CR with incomplete blood count recovery (CRi) within 3 months and maintained for 28 day. The secondary endpoints include CR/CRi with undetectable minimal residual disease (MRD), duration of remission, event-free survival, overall survival, cellular kinetics and safety5.

About T-ChargeT-Charge is a next-generation CAR-T platform, innovated at the Novartis Institutes for BioMedical Research (NIBR), that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. By implementing the T-Charge platform, we aim to revolutionize CAR-T cell therapy with new products that have the potential to offer patients a higher likelihood of better and more durable responses, improved long-term outcomes and a reduced risk of severe adverse events. The T-Charge platform preserves T cell stemness (T cell ability to self-renew and mature), an important T cell characteristic closely tied to its therapeutic potential, which results in a product containing greater proliferative potential and fewer exhausted T cells. With T-Charge, CAR-T cell expansion occurs primarily within the patients body (in-vivo), eliminating the need for an extended culture time outside of the body (ex-vivo). The T-Charge platform, which implements important process efficiencies, will be rapid, compared with traditional CAR-T, and reliable, through simplified processes and streamlined quality control. Multiple CAR-T therapies, including YTB323 and PHE885, are being developed using the Novartis T-Charge platform.

About Novartis commitment to Oncology Cell TherapyAs part of the unique Novartis strategy to pursue four cancer treatment platforms radioligand therapy, targeted therapy, immunotherapy and cell and gene therapy we strive for cures through cell therapies in order to enable more patients to live cancer-free. We will continue to pioneer the science and invest in our manufacturing and supply chain process to further advance transformative innovation.

Novartis was the first pharmaceutical company to significantly invest in pioneering CAR-T research and initiate global CAR-T trials. Kymriah, the first approved CAR-T cell therapy, developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania, is the foundation of the Novartis commitment to CAR-T cell therapy.

We have made strong progress in broadening our delivery of Kymriah, which is currently available for use in at least one indication in 30 countries and at more than 370 certified treatment centers, with clinical and real-world experience from administration to more than6,900 patients. We continue to pioneer in cell therapy, leveraging our vast experience to develop next-generation CAR-T cell therapies. These therapies will utilize our new T-Charge platform being evaluated to expand across hematological malignancies and bring hope for a cure to patients with other cancer types.

DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as potential, can, will, plan, may, could, would, expect, anticipate, seek, look forward, believe, committed, investigational, pipeline, launch, or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AGs current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisNovartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more athttps://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnewsFor Novartis multimedia content, please visit https://www.novartis.com/news/media-libraryFor questions about the site or required registration, please contact media.relations@novartis.com

References

# # #

Novartis Media RelationsE-mail: media.relations@novartis.com

Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com

Continue reading here:
Novartis five-year Kymriah data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL -...

ipopba/iStock via Getty Images

Arcellx (NASDAQ:ACLX) is a clinical-stage biotech whose stated goal is to develop potentially "safer, more effective, and more broadly accessible" CAR-T cell therapies for cancers and incurable diseases.

For anyone who is unfamiliar with CAR-T cell therapy, the following is an easy-to-understand explanation from National Cancer Institute.

cancer.gov

Simply put, CAR T-cell therapy is using & equipping patients' own T-cells to recognize, tag, and destroy cancer cells.

Currently, there are six CAR-T cell therapies approved by the FDA to treat five types of refractory* or relapsed* blood cancers (see below), including relapsed or refractory multiple myeloma (r/r MM).

*Note: Refractory means a cancer has stopped responding to treatments; Relapsed means a cancer has come back.

cancer.gov

Before I dive into ACLX's data in r/r MM, I would like to cover briefly what the company says about its underlying technology, which ACLX believes has the potential to produce "Best-in-Class" CAR-T cell therapies.

In order for a CAR-T cell therapy to work, the engineered T-cells, capable of expressing cancer-specific CAR (Chimeric Antigen Receptor), need to accomplish two very important tasks:

1. to recognize and tag the cancer cells by binding to the target antigen, e.g. CD19, BCMA, that is highly expressed on the surface of cancer cells;

2. once that part is done, the engineered T-cells then are activated (or signaled) to kill the tagged cancer cells.

According to the National Institute of Cancer, much innovation has taken place on the signaling part (that's inside the T-cells), see below.

cancer.gov

According to ACLX, their innovation is on the Antigen-binding domain (on the outside of T-cells, called D-Domain, which is smaller and more stable than the binding domains of other CAR-T therapies (below, slide 6).

ACLX thinks that these differences in the binding domain can potentially lead to improvements in safety, efficacy, and availability of their ddCAR T-cell therapy which they called ARC- (Antigen Receptor Complex) T cells.

ACLX June 2022 presentation

Furthermore, ACLX believes their ARC-T cell therapy can work with their second proprietary platform, called ARC-SparX platform.

SparX [proteins] stands for soluble protein antigen-receptor X-linker.

ACLX believes that this platform can develop novel CAR-T cell therapies that, unlike the current ones, are "dosable, controllable, and adoptable" T-cell therapies.

For anyone interested, there is a ~2min video on the company website explaining how ARC-SparX is supposed to work.

ACLX website

The cell (in light blue) with light blue tags on the outside represents the ARC-T cells.

The upside-down Y shape thing represent SparX proteins which have two ends, i.e. the Universal-tag end (a white-ish tag) that binds to ARC-T cells, and antigen-receptor end (in purple) that binds to the antigens (in pinkish color) on cancer cells.

So patients are dosed with SparX proteins that are designed to recognize and bind to antigen on cancer cells on the one end and bind to ARC-T cells on the other hand, which would activate the ARC-T cells to kill the tagged cancer cells.

In theory, SparX will recognize and bind to antigens that are specific to each cancer, and ARC-T cells are only activated when bound to SparX which are already bound to cancer cells.

Therefore by controlling SparX proteins, e.g. dose or antigen-receptor design, ACLX believes that such ARC-SparX T-cell therapy can potentially be " dosable, controllable, and adoptable", i.e. one-time infusion of ARC-T cells, but different doses or antigens of SparX proteins, if necessary.

I find this rationale very interesting and I can see it being very impactful & beneficial as a cancer treatment if successfully developed.

Let us now turn to the results presented at the 2022 ASCO meeting that seems to have impressed the market.

ACLX announced the presentations at ASCO on Friday, June 3, which must have impressed the market, as on Monday, June 6, the stock of ACLX rose 20%, i.e. from $13.09 to $15.79, see below.

ACLX 5-day chart ending on June 7, 2022 (Seeking Alpha)

The table below lists the headlines from ACLX's r/r MM p1 trial:

(Source: Emphasis by author)

To put these data in context, ACLX presents a table comparing their results with other approved MM treatments (see below):

ACLX presentation

As can be seen above, relative to other approved treatments for MM, ACLX's lead candidate CART-ddBCMA showed very promising efficacy and safety data so far, i.e. best ORR (100%), best safety (0% in Grade3/4 CRS [Cytokine release syndrome]).

Perhaps the strong efficacy and safety r/r MM p1 data so far explains the enthusiastic price action by the market.

More on this next.

According to ACLX, MM is the third most common blood cancer, affection 100,000 patients per year, and total addressable market by T-cell therapy is around $10B, see below.

ACLX ASCO 2022 presetation

It is important to remember ACLX's r/r MM data, though very promising, are early data, which means that one cannot assume too much.

In the same PR, the company mentioned that a pivotal p2 trial is on track to start by YE 2022, and if the pivotal trial is successful, the company anticipates BLA (Biologic License Application) filing to take place in 1H 2025 (slide 10).

As discussed in these market reports (here, here), CART-ddBCMA's early data seem to be "in-line" with the current CAR-T therapy leader, Carvykti, from Johnson & Johnson (JNJ) and Legend Biotech (LEGN).

A bullish outlook will be that CART-ddBCMA, continues to report positive data both in p1 & pivotal p2 trial, and ultimately be approved & commercialized.

As seen above, CART-ddBCMA has the potential to be safer and more effective than the currently available MM treatments, CAR-T or other therapies.

If so, then CART-ddBCMA will no doubt be very competitive in this space, translating in a significant potential upside.

For example, LEGN's lead CAR-T cell therapy, Carvykti, was approved in March 2022, and LEGN is currently valued at $7.09B (on June 7), 15 times ACLX's $467M market cap.

Or even if it's only comparable, as availability of CAR-T therapies is a rate-limiting step (more demand than the supply), a newly approved CAR-T should still be making very meaningful contribution to MM patients.

Significant risks to the investment thesis include but are not limited to: disappointing p1 & p2 data or trial failures, delays or difficulties in manufacturing, CMC (chemistry, Manufacturing, Control) data, delays or failures in regulatory process, dilution risks, etc.

According to the latest 10Q (page 18), as of March 31, 2022, ACLX had cash and cash equivalents and marketable securities of $210.9 million and a net loss of $32.4M in Q1, 2022.

The company believes the cash position is "adequate to fund operations into the second half of 2023".

This article on ACLX marks a personal-first for me: it's my first SA article covering a cancer drug. In the past, I have largely stayed away from the oncology space, due to very high failure rate of cancer trials.

Hopefully, this marks the beginning of something good.

As I have expressed many times in my past bullish articles, small clinical-stage biotech stocks are highly speculative and price action volatile. While good news does not always send the stock upwards, bad news will certainly send it down.

In the recent days, the short-term price action of the whole biotech sector is even more volatile and seemingly driven by anything but company-specific material news, as seen in ACLX's 1 year chart.

ACLX 1-year chart ending on June 7, 2022 (Seeking Alpha)

While it is very encouraging to see a clearly positive move to ACLX's r/r MM data, there is no guarantee that this stock, has turned to a sustainable up-trend.

With this in mind, please invest prudently with only money you are prepared to lose, if after doing your own due diligence, you find the upside potential suits your risk tolerance and investment time frame.

Thanks for reading and wishing you all the best!

View original post here:
Arcellx: Speculative Buy For Their CAR-T Cell Therapy (NASDAQ:ACLX) - Seeking Alpha

The first CAR-T cell therapy, a type of gene therapy, to treat cancers of blood and lymphatic system is likely to be available in India from 2023, offering hope to patients who cant afford to travel abroad for the expensive treatment.

On June 11, ImmunoACT, an Indian Institute of Technology, Bombay spin-off company, launched its facility to start production on a large scale. As of now, CAR-T cell therapy is not available in India, Patients have to travel to countries like the US and it costs nearly Rs 3-4 crore.

The indigenously developed CAR-T cell therapy was the result of intense research over the last eight years and had now been patented,Rahul Purwar, a senior IIT-Bombay faculty who is also the founder and CEO of ImmunoACT, said.

Incubated at the Society of Innovation and Entrepreneurship at IIT-B, ImmunoACT now has Hyderabad-based pharmaceutical major Laurus Labs as a partner and is looking to make the treatment available at Rs 20-30 lakh a patient in India, the company said.

The facility has the capacity to treat nearly 1,200 patients a year.

As part of the therapys Phase-1 clinical trial at Tata Memorial Hospitals Advanced Centre for Treatment, Research and Education in Cancer in Mumbai, 10 lymphoma patients have been treated with no relapse so far.

The company is now looking to seek regulatory approvals from the Central Drugs Standard Control Organisation for Phase 2 trials with about 40 patients.

In its initial trials, the project received support from the Centres department of biotechnology and Biotechnology Industry Research Assistance Council.

What is CAR-T Cell therapy?

Chimeric Antigen Receptor (CAR)- T cells are a patients own immune cells, which are engineered in the laboratory to fight cancer.

It is mostly effective in blood cancer and lymphoma (cancer beginning in the cells of the lymph system), though studies are on to assess its role in solid tumours and auto-immune diseases as well.

Also read:Explainer | Dostarlimab for cancer cure: Hope or hype?

As of now, the therapy is usually offered as second-line treatment for late-stage leukemia and lymphoma patients who are either not responding to conventional treatments like chemotherapy and bone-marrow transplant or have a case of relapsed cancer.

Research from abroad has shown that the therapy can be effective in 40-50 percent of the patients, with slightly better results in pediatric populations.

Estimates suggest that about 40,000-50,000 new leukemia and lymphoma patients are diagnosed in India every year.

Ray of hope for cancer patients in India

According to Puwar, ImmunoACT's patented CAR-T cell platform provides a unique design algorithm to develop novel CAR-T cells and its first product, HCAR19, showed favourable balance of efficacy and toxicity.

It can be offered to patients with CD19 marker in B cells (the protein that is used to diagnose cancers that arise from B type of cellwhite blood cells that produce antibodies such as B cell lymphomas, acute lymphoblastic leukemia, and chronic lymphocytic leukemia), said Purwar.

He said that the majority of B cell malignancies have normal to high levels of CD19.

Also read:Current surge in Covid-19 cases not start of fourth wave, say authorities

The majority of the commercially available CAR-T cell therapies are also associated with severe toxicity, Purwar said, adding the therapy developed in India was far better on that count.

He also said that the therapy was likely to be available at cancer hospitals after the Phase 2 trial of the research projects, while the late-stage trial would continue concurrently.

Visit link:
Ray of hope for blood cancer, lymphoma patients as CAR-T cell therapy to be available in India - Moneycontrol

Objective: to clinically validate efficacy of a new form of immunotherapy utilizing CAR-T cells to target multiple difficult-to-treat tumors

PARIS, June 13, 2022 /PRNewswire/ -- Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, today announced the kick-off of their participation in the prestigious Hospital-University Research in Health (RHU) program. Designed by France's National Research Agency, the RHU funding supports cutting-edge research and cross-institutional collaborations, bringing together academia, businesses, and hospitals to push the boundaries of what is possible in healthcare.

In December of 2021, 17 proposals were selected for the RHU funding. Among them, receiving close to 10 million euros, is the EpCART project. Under the leadership of Sebastian Amigorena, Ph.D., one of Mnemo's scientific co-founders and head of the Immune Responses and Cancer Team at Institut Curie, the EpCART project aims to clinically validate a novel approach to CAR-T immunotherapy.

"We are honored to be named a laureate for this prestigious initiative and work alongside our long-standing partners at Institut Curie, as well as the MEARY Cell and Gene Therapy Center at Saint-Louis Hospital, AP-HP," said Mnemo CEO, Robert LaCaze.

The EpCART project focuses on epigenetic reprogramming of CAR-T cells. Through the inactivation of SUV39H1, a key enzyme in the differentiation pathway of T cells, the memory phenotype of these cells can be greatly increased. This works to achieve long-lasting tumor control, addressing patient relapse.

"Current immuno-oncology therapies often suffer from immune-cell memory loss, causing therapies to become less active and persistent in their ability to attack cancer cells over time," said Dr. Amigorena. "The EpCART project mines insights into the memory of the immune system to overcome this challenge and produce a new class of CAR-T therapies with enhanced memory and persistence. We believe this will drive more durable responses for cancer patients."

Over the next five years, the EpCART project will seek to clinically validate this technology as an autologous therapy. Mnemo will work in collaboration with the other EpCART partners to conduct a Phase I-II clinical trial, investigating the activity of these innovative CAR-T therapies in a cohort of 35 patients with difficult-to-treat solid tumors.

The EpCART project will accelerate research on Mnemo's EnfiniT Discovery Engine, an integrated drug discovery tool combining key technologies to create lasting immune memory, identify novel cancer-specific targets, and more.

"Today is an exciting step in our journey to develop transformational immunotherapies with the aim of improving the body's ability to detect, fight, and overcome cancer," said Mnemo Co-Founder and Chief Operating Officer, Alain Maiore. "We are truly honored to collaborate with such esteemed partners and look forward to the fruits of this initiative."

About Mnemo Therapeutics

Mnemo is developing transformational immunotherapies to improve the body's ability to fight and overcome cancer. Integral to Mnemo's approach is the EnfiniT Discovery Engine, composed of key technologies that work to identify novel cancer-specific antigens and enhance immune cells' memory and persistence. Mnemo will harness these technologies with multiple modalities across a range of oncology indications, engineering the future of immunotherapies to transform the lives of people with cancer. Mnemo is headquartered in Paris with an office in New York City, and it maintains state of the art laboratories in Paris, New York, and Princeton, New Jersey. The company leverages an international talent pool and global resources in its quest to create immunological cures.

SOURCE Mnemo Therapeutics

Go here to read the rest:
Mnemo Therapeutics Launches RHU Project in Collaboration with Leading European Research Partners, Institut Curie and MEARY Cell and Gene Therapy...

SEATTLE and PESSAC, France, June 10, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, and TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), announced today that they have entered into a collaboration to evaluate Umojas iPSC platform within TreeFrogs C-Stem technology for scalable expansion and immune cell differentiation in bioreactors.

Together, the successful pairing of Umojas RACR engineered iPS cells and TreeFrogs C-Stem technology could overcome several challenges facing ex vivo allogeneic therapies, said Ryan Larson, Ph.D., Vice President and Head of Translational Science at Umoja. Two major industry-wide challenges include the ability to scale iPSC-based culture while maintaining cell health, quality, and efficient immune cell differentiation. TreeFrogs biomimetic C-Stem technology is the perfect complementary development platform for our RACR technology, a pairing which could result in controlled, efficient iPSC expansion and differentiation into immune cells, with improved yields and quality. In addition to enhancing the differentiation and yield of immune cells within the manufacturing process, our RACR system should bring therapeutic benefit to patients, allowing for safe in vivo engraftment and persistence of tumor-killing cells without requirements for toxic lymphodepleting chemotherapy.

Umoja is developing an engineered iPSC platform that addressesmany challenges associated with ex vivo cell therapy manufacturing, including limited scalability and manufacturing complexity.Umojas iPSCs are engineered with a synthetic rapamycin-activated cytokine receptor (RACR) to drive differentiation to, and expansion of innate cytotoxic lymphoid cells, including but not limited to natural killer (NK) cells in the absence of exogenous cytokines and feeder cells. TreeFrogs proprietary C-Stem technology relies on the high-throughput encapsulation (>1,000 capsules/second) of hiPSCs within biomimetic alginate shells, which promote in vivo-like exponential growth and protect cells from external stress. In 2021, C-Stem was demonstrated to allow for unprecedented iPSC expansion in 10L bioreactors, while preserving stem cell quality. Also enabling direct in-capsule iPSC differentiation, C-Stem constitutes a scalable, end-to-end, and GMP-compatible manufacturing platform for iPSC-derived cell therapies.

Frdric Desdouits, Ph.D., Chief Executive Officer at TreeFrog added, Our primary goal is to bring the benefits of the C-Stem technology to patients as fast as possible, either through in-house programs or strategic alliances with cell therapy leaders. Partnering with Umoja is an important step forward in immuno-oncology. Besides scale-up and cell quality, the in vivo persistence of allogeneic therapies remains a critical challenge in the industry. We believe Umojas platform will allow for safer and more efficient allogeneic cell therapies in immuno-oncology. We look forward to rapidly advancing this joint approach to clinic and contributing to the future of off-the-shelf cancer treatments.

About Umoja BiopharmaUmoja Biopharma, Inc. is an early clinical-stage company advancing an entirely new approach to immunotherapy. Umoja Biopharma, Inc. is a transformative multi-platform immuno-oncology company founded with the goal of creating curative treatments for solid and hematological malignancies by reprogramming immune cells in vivo to target and fight cancer. Founded based on pioneering work performed at Seattle Childrens Research Institute and Purdue University, Umojas novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform, and the TumorTag targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives. To learn more, visithttp://umoja-biopharma.com/.

About TreeFrog TherapeuticsTreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 80 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline in regenerative medicine and immuno-oncology. The company is currently opening technological hubs in Boston, USA, and Kobe, Japan, to drive the adoption of C-Stem and build strategic alliances with leading academic, biotech and industry players in the field of cell therapy.

Umoja Biopharma Media Contact:Darren Opland, Ph.D.LifeSci Communicationsdarren@lifescicomms.com

TreeFrog Therapeutics Media Contact:Pierre-Emmanuel GaultierTreeFrog Therapeuticspierre@treefrog.fr

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/012ae87d-b7c6-4fa2-81dc-c769877b182c

Link:
Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology...

This report studies the Dendritic Cell Therapy Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Dendritic Cell Therapy Market analysis segmented by companies, region, type and applications in the report.

The report offers valuable insight into the Dendritic Cell Therapy market progress and approaches related to the Dendritic Cell Therapy market with an analysis of each region. The report goes on to talk about the dominant aspects of the market and examine each segment.

Key Players: Dendreon Pharmaceuticals LLC, Merck KGaA, Glaxo SmithKline plc, Northwest Biotherapeutics, Inc, JW CreaGene, Immunocellular Therapeutics Inc, Argos Therapeutics, Bellicum Pharceuticals, Inc.

Get Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-dendritic-cell-therapy-market-4452170?utm_source=dj&utm_medium=41

The global Dendritic Cell Therapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Dendritic Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2022-2026.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Research objectives:

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

Key questions answered in this report

Table of Contents: Dendritic Cell Therapy Market

Make an enquiry before buying https://www.reportsandmarkets.com/enquiry/global-dendritic-cell-therapy-market-4452170?utm_source=dj&utm_medium=41

About Us:

Our marketing research reports comprise of the best market analysis along with putting the right statistical and analytical information on the markets, applications, industry analysis, market shares, technology and technology shifts, important players, and the developments in the market. If you require any specific company, then our company reports collection has countless profiles of all the key industrial companies. All these reports comprise of vital information including the company overview, the company history, the business description, the key products & services, the SWOT analysis, the crucial facts, employee details, the locations and subsidiaries to name a few.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

The post What are the Dendritic Cell Therapy Market Strategies? appeared first on Agency.

View original post here:
What are the Dendritic Cell Therapy Market Strategies? - Digital Journal